<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58760">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980134</url>
  </required_header>
  <id_info>
    <org_study_id>MORDIS Study 010044-002</org_study_id>
    <nct_id>NCT01980134</nct_id>
  </id_info>
  <brief_title>The MORDIS Study Clinical Investigational Plan</brief_title>
  <acronym>MORDIS</acronym>
  <official_title>Multicenter, Open, Prospective Study on Modified Resect and DIScard Strategy of Small Colonic Lesions Using WavSTAT4 Optical Biopsy System: The MORDIS Study Clinical Investigational Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SpectraScience</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Policlinico Universitario Gemeli, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Institute of Oncology, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut des Maladies de l'Appareil digestif, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Européen Georges-Pompidou, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University Hospitals Leuven, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innere Medizin I Interdisziplinäre Endoskopie Universitätsklinikum Tübingen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nuremberg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital Herlev, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SKANE University Hospital Malmö, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Insitute for Clinical and Experimental Medicine Prague, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SpectraScience</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the use of WavSTAT4 system during colonoscopy in identifying diminutive
      colorectal lesions (e.g. hyperplastic polyps) that can be resected and discarded (or even
      left in-situ) without adverse clinical impact.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the performance of the WavSTAT4 Optical Biopsy System when used at multiple
      centers.

      Endpoint targets are based on the ASGE PIVI recommendations on real-time endoscopic
      assessment of the histology of diminutive colorectal polyps.

        -  Primary endpoint: To demonstrate potential of the WavSTAT4 Optical Biopsy System to
           predict adenomatous histology with a NPV &gt; = 90% for diminutive colorectal lesions.

        -  Secondary Endpoint: To show that use of the WavSTAT4 system used to determine histology
           of colorectal polyps ≤5 mm in size, when combined with the histo- pathologic assessment
           of polyps &gt;5 mm in size, provides a ≥ 90% agreement in assignment of post-polypectomy
           surveillance intervals when compared to decisions based on pathology assessment of all
           identified polyps.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>To demonstrate potential of the WavSTAT4 Optical Biopsy System to predict adenomatous histology with a NPV &gt; = 90% for diminutive colorectal lesions.</measure>
    <time_frame>WavSTAT4 Optical Biopsy System gives real-time result. Outcomes are measured when comparing the physician and WavSTAT4 system result to pathology results, which usually take one to two weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The WavSTAT4 Optical Biopsy System result will be compared to physician visual diagnosis as well as the subsequent pathological report.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved determination of post-polypectomy surveillance intervals</measure>
    <time_frame>Outcome is measured when patients return for routine follow up. which is a long-term study as patients are not usually requested to return for another colonoscopy for many years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>To show that use of the WavSTAT4 system used to determine histology of colorectal polyps ≤5 mm in size, when combined with the histo- pathologic assessment of polyps &gt;5 mm in size, provides a ≥ 90% agreement in assignment of post-polypectomy surveillance intervals when compared to decisions based on pathology assessment of all identified polyps.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Adenoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will be sent for pathological examination and potentially used for other research
      purposes.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ~1200 patients ≥ 18 years of age at the time of enrollment showing presence of diminutive
        colorectal polyps.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female &gt; 18 years

          -  Standard indication for colonoscopy OR CRC screening OR follow-up examination after
             the diagnosis of one or more established polyps OR polypectomy (analysis of polyps
             other than the intended polypectomy)

          -  Written informed consent

        Exclusion Criteria:

          -  Inflammatory bowel disease

          -  Hereditary/genetic polyposis syndromes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Costamagna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Gemeli, Roma, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guido Costamagna, MD</last_name>
    <phone>+390630154083</phone>
    <email>gcostamagna@rm.unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinika Hepatogastroenterologie Ikem</name>
      <address>
        <city>Praha</city>
        <zip>Praha 4</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MUDR. M. Benes, MD</last_name>
      <phone>420 26136 4016</phone>
    </contact>
    <contact_backup>
      <last_name>Prof. Julius Spicak, MD</last_name>
      <phone>420 26136 4016</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vilmann, MD</last_name>
      <phone>4991318545053</phone>
      <email>Peter.Vilmann@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts Klinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Götz,, M.D.</last_name>
      <phone>+49 7071 29 82162</phone>
      <email>martin.goetz@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nisar Peter Malek, M.D.</last_name>
      <phone>+49 7071 29 82162</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiano Crosta, MD</last_name>
      <phone>+ 390257489067</phone>
      <email>cristiano.crosta@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Christiano Crosta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemeli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Costamagna, MD</last_name>
      <phone>+ 390630154083</phone>
      <email>gcostamagna@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Guido Costamagna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SKANE University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ervin Toth, MD</last_name>
      <phone>46 40 33 1000/ 33 86 21</phone>
      <email>ervin.toth@med.lu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Ignjatovic A, East JE, Suzuki N, Vance M, Guenther T, Saunders BP. Optical diagnosis of small colorectal polyps at routine colonoscopy (Detect InSpect ChAracterise Resect and Discard; DISCARD trial): a prospective cohort study. Lancet Oncol. 2009 Dec;10(12):1171-8. Epub 2009 Nov 10.</citation>
    <PMID>19910250</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenomatous colorectal lesions</keyword>
  <keyword>colorectal polyps</keyword>
  <keyword>polyps</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
